Pembrolizumab in HER2-Positive Gastric Cancer
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Akihito Kawazoe(National Cancer Center Hospital East), Yuxian Bai(Harbin Medical University), Jianming Xu, Sara Lonardi(Istituto Oncologico Veneto), Jean Phillipe Metges(Centre Hospitalier Régional Universitaire de Brest), Patricio Yañez, Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Lin Shen, Yuriy Ostapenko(National Cancer Institute), Mehmet Bilici(Atatürk University), Hyun Cheol Chung(Yonsei University), Kohei Shitara(National Cancer Center Hospital East), Shukui Qin, Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero(Vall d'Hebron Hospital Universitari), Suxia Luo(Henan Cancer Hospital), Mauricio Mahave(Fundación Arturo López Pérez), Yong Tang(Xinjiang Medical University), Maeve A. Lowery(St. James's Hospital), Maria Marcela Monteiro(Hospital Haroldo Juaçaba), Linzhi Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chie‐Schin Shih(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kanu Sharan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sun Young Rha(Yonsei University)
Cited by 55Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis